Tuberculin skin test results in HIV-infected patients in India: implications for latent tuberculosis treatment

被引:0
作者
Swaminathan, S. [1 ]
Subbaraman, R. [2 ]
Venkatesan, P. [1 ]
Subramanyam, S. [1 ]
Kumar, S. R. [1 ]
Mayer, K. H. [3 ]
Narayanan, P. R. [1 ]
机构
[1] TB Res Ctr, HIV AIDS Div, Madras 600031, Tamil Nadu, India
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[3] Brown Univ, Div Infect Dis, Providence, RI 02912 USA
关键词
HIV; tuberculin skin test; latent tuberculosis infection; anergy; India;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
OBJECTIVE: To evaluate the utility of the tuberculin skin test (TST) in detecting latent and active tuberculosis (TB) among human immunodeficiency virus (HIV) infected patients in South India. DESIGN: TSTs and CD4 counts were collected from 631 HFV-infected individuals without active TB and 209 anti-retroviral and anti-tuberculosis treatment-naive HIV-infected patients with TB. We calculated the proportion of TST-positive individuals, as well as the sensitivity, specificity, positive predictive value (PPV) and negative predictive value of TST in the diagnosis of TB. RESULTS: Among subjects without active TB, 28% with a CD4 count < 100 cells/mu l vs. 43% of the total cohort had a TST > 5 mm (P = 0.14), while the proportions with induration > 10 mm were 14% vs. 36%, respectively (P < 0.01). Among those with active TB, using a 5 mm cut-off, the sensitivity was 42% for those with CD4 counts < 200 cells/mu l compared to 70% for those with CD4 counts >= 200 cells/mu l (P < 0.001). The PPV for detecting active TB was 29%. CONCLUSIONS: TST is a poor predictor of both latent and active TB in HIV-infected individuals in TB endemic countries. Programmes offering treatment for latent TB should consider including all HIV-positive patients regardless of TST status, or use other indicators, such as CD4 count.
引用
收藏
页码:168 / 173
页数:6
相关论文
共 26 条
[1]  
AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008
[2]  
[Anonymous], TAM NAD HUM DEV REP
[3]  
Balasubramanian R, 2004, INT J TUBERC LUNG D, V8, P323
[4]   Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials [J].
Bucher, HC ;
Griffith, LE ;
Guyatt, GH ;
Sudre, P ;
Naef, M ;
Sendi, P ;
Battegay, M .
AIDS, 1999, 13 (04) :501-507
[5]   Tuberculin skin testing in patients with HIV infection: Limited benefit of reduced cutoff values [J].
Cobelens, Frank G. ;
Egwaga, Saidi M. ;
van Ginkel, Tessa ;
Muwinge, Hemed ;
Matee, Mecky I. ;
Borgdorff, Martien W. .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (05) :634-639
[6]   Diagnostic standards and classification of tuberculosis in adults and children [J].
Dunlap, NE ;
Bass, J ;
Fujiwara, P ;
Hopewell, P ;
Horsburgh, CR ;
Salfinger, M ;
Simone, PM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) :1376-1395
[7]  
Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192
[8]   Screening people living with HIV before tuberculosis preventative therapy [J].
Godfrey-Faussett, P ;
Quigley, M ;
Ayles, H ;
Mwinga, A ;
Hosp, M ;
Porter, J .
AIDS, 1999, 13 (15) :2190-2191
[9]   Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis [J].
Gourevitch, MN ;
Hartel, D ;
Selwyn, PA ;
Schoenbaum, EE ;
Klein, RS .
AIDS, 1999, 13 (15) :2069-2074
[10]   PREVALENCE OF TUBERCULIN POSITIVITY AND SKIN-TEST ANERGY IN HIV-1-SEROPOSITIVE AND HIV-1-SERONEGATIVE INTRAVENOUS-DRUG-USERS [J].
GRAHAM, NMH ;
NELSON, KE ;
SOLOMON, L ;
BONDS, M ;
RIZZO, RT ;
SCAVOTTO, J ;
ASTEMBORSKI, J ;
VLAHOV, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (03) :369-373